Testing if lab drug screening can predict cancer treatment responses
Ex Vivo Multi Drug Screening of Solid Tumours to Determine Personalised Therapy Efficacy and Resistance
This study is testing if a new way of checking how tumors respond to different cancer treatments can help doctors choose the best options for patients with solid tumors like bladder or kidney cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Sheffield Teaching Hospitals NHS Foundation Trust Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Sheffield, South Yorkshire) |
| Trial ID | NCT05231655 on ClinicalTrials.gov |
What this trial studies
The EVIDENT study aims to evaluate whether ex vivo drug screening can accurately predict the response of patients with solid tumors to standard cancer treatments. Eligible participants will provide fresh tumor samples during surgery, biopsy, or fluid aspiration, which will then be tested against various therapies, including both standard and novel treatments. The study will compare the results of these screenings with the actual clinical outcomes of the patients' treatments to assess the predictive accuracy of the screening method. This feasibility study will initially focus on bladder cancer, kidney cancer, melanoma, sarcoma, and glioblastoma, with potential to expand to other solid tumors in the future.
Who should consider this trial
Good fit: Ideal candidates include individuals over 16 years old with a diagnosis of solid cancer who are scheduled for surgery, biopsy, or fluid aspiration.
Not a fit: Patients with known blood-borne viruses such as Hepatitis B, Hepatitis C, or HIV may not benefit from this study due to safety concerns in laboratory handling.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective cancer treatments for patients.
How similar studies have performed: While the concept of ex vivo drug screening is gaining traction, this specific approach is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \>16 years of age with a diagnosis of known or suspected solid cancer who will undergo surgery, biopsy, aspirate, or TURBT Willing to donate a section fresh tumour tissue from surgery, a TURBT, fluid aspirate, or biopsy surplus to diagnostic use Willing to donate a 9ml blood sample Able to give written informed consent Previously treated patients are eligible if: * Present with a recurrence of a previously treated tumour. This may be a local or metastatic recurrence * Have undergone treatment for their cancer, but fail to respond to this and progress * Have received neoadjuvant therapy for their tumour * Have undergone chemotherapy, targeted therapy, immunotherapy, hormone therapy and or radiotherapy for a previous tumour Exclusion Criteria: Patients with a known diagnosis of a blood borne virus (Hepatitis B, Hepatitis C, HIV). (The laboratories where experiments will be conducted do not have the safety facilities to use material containing these pathogens) Patients with a current positive COVID-19 infection
Where this trial is running
Sheffield, South Yorkshire
- Sheffield Teaching Hospitals NHS Foundation Trust — Sheffield, South Yorkshire, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Sarah Danson, PhD, FRCP — University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust
- Study coordinator: Greg Wells, PhD
- Email: g.wells@sheffield.ac.uk
- Phone: +44 114 215 9098
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.